跳至主要内容
临床试验/2025-524819-37-00
2025-524819-37-00招募中4 期

TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre3 个研究点 分布在 1 个国家目标入组 345 人开始时间: 2026年3月2日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
345
试验地点
3
主要终点
The change in Apnea–Hypopnea Index (AHI) at 6 months

研究概览

简要总结

The primary outcome will be the change in OSA severity from baseline to the 6-month follow-up.

入排标准

年龄范围
65 years 至 65+ years(65+ Years)
接受健康志愿者

入选标准

  • Age ≥65 years.
  • Diagnosis of moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥15 events/h), determined by a home-based sleep apnea test, with clinical indication for active treatment according to the International Consensus Document on OSA (PMID: 33875282)
  • Overweight or obesity (body mass index [BMI] ≥27 kg/m²), consistent with recommendations for semaglutide use in individuals with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

排除标准

  • Presence or suspicion of another sleep disorder.
  • >50% central apneas or Cheyne–Stokes respiration
  • Excessive daytime sleepiness (Epworth Sleepiness Scale ≥18)
  • Participation in a weight-loss program
  • Inability to adhere to interventions or assessments
  • Type 1 or type 2 diabetes.
  • Severe chronic illness (e.g., neoplasia, renal failure, severe COPD, chronic depression).
  • Social or geographic limitations affecting adherence.
  • Any clinical indication for which continuous positive airway pressure (CPAP) is deemed mandatory by the referring physician.

结局指标

主要结局

The change in Apnea–Hypopnea Index (AHI) at 6 months

The change in Apnea–Hypopnea Index (AHI) at 6 months

次要结局

  • Cost-effectiveness.
  • Blood pressure.
  • OSA pathophysiology (hypoxic burden, delta heart rate, loop gain).
  • Symptoms (daytime sleepiness).
  • Functional and psychological domains (quality of life, sleep quality, circadian rest-activity rhythm, cognitive function, mental health).
  • Body weight.
  • Molecular mechanisms (biomarkers of inflammation, oxidative stress, obesity, and cardiovascular risk).

研究者

发起方
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
申办方类型
Laboratory/Research/Testing facility
责任方
Principal Investigator
主要研究者

Diego Arango Del Corro

Scientific

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

研究点 (3)

Loading locations...

相似试验